Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders

Additionally, potential medicinal applications are being investigated using strains of European Union certified hemp

July 31, 2014

COLORADO SPRINGS, Colo., July 31, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of proprietary formulations for clinical drug development to bring the cannabis formulations to market for critical ailments such as cancer and neurological disorders.

Mr. Mario S. Lap, Director and President of European Operations, stated, "Cannabis Science intends to leverage its team's expertise to create a framework for research and clinical testing. We are excited to report further development and progress as we proceed forward."

The facilities are located in the Alicante region of Spain, and the Company is working with a local partner to initiate an agricultural program, to prepare GMP production and to start building the research framework to conduct scientific testing of extracts and the active constituents contained in the cannabis plant with the objective of developing selected formulations for clinical use.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1.561.420.4824

Raymond C. Dabney, Management Consultant, Co-Founder
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 1.310.650.3788

Come join our Patient Access Center. Allows poeple to be open about their cannabinoid therapies